Novo Nordisk stock holds steady as Wegovy pill launch drives Q1 sales beat

Traders Union
All News
Financial News
Novo Nordisk gains 0.81% on earnings

Highlights

Novo Nordisk exceeded Q1 profit estimates as surging Wegovy pill sales contributed DKK 2.3 billion and patient uptake surpassed one million since January.
The company completed the first phase of its DKK 15 billion share buyback and benefited from a US drug program provision reversal, but underlying sales declined modestly absent this effect.
Shares show strong short-term momentum and trade near $44.75 with overbought signals, but technicals indicate risk of a pullback and a likely sideways range between $44.70–$46.10 over the next week.

Operating gain exceeds forecasts as Wegovy pill and buybacks lift results

Novo Nordisk's first-quarter results revealed adjusted operating profit of DKK 32,858 million, outperforming expectations due to robust uptake of its newly launched Wegovy pill, which contributed DKK 2.3 billion to Q1 sales and enrolled over one million patients since January. The company completed the first tranche of its DKK 15 billion share buyback program, reducing float and enhancing per-share value, while a provision reversal related to the US 340B Drug Pricing Program gave an additional boost to reported sales. Adjusted sales excluding this effect saw a modest decline, partially cushioned by ongoing volume growth in GLP-1 therapies, and Novo Nordisk is also gearing up for the launch of oral Ozempic in the coming week.

Overbought risk emerges as momentum and volatility intensify near resistance

Technically, NVO trades above MA-20 ($40.44) and MA-50 ($38.68), with the MA-200 ($49.87) overhead as long-term resistance. The D1 Ichimoku Kijun at $40.11 implies immediate support just below current levels. Momentum remains positive, confirmed by a MACD Buy signal and positive Awesome Oscillator, with ADX reading 17.5 showing only a mild trend. However, RSI at 70.69, CCI at 172.23, and Stoch RSI at 100 all indicate pronounced overbought conditions, while BBP further confirms buyer dominance. The price is currently near the upper end of today's intraday range ($44.21–$45.12), reflecting heightened volatility and sustained buying pressure, though the combination of overbought oscillators with strong momentum introduces the risk of a short-term pullback.

Pullback risk rises as overbought signals outweigh limited upside

Over the next five trading days, NVO is likely to fluctuate within a typical volatility band of $44.70–$46.10. With a low probability of further gains (less than 20%), a pullback scenario is more likely as overbought conditions persist. The baseline expectation calls for price stabilization in a sideways pattern near current levels. Upside action would require a decisive breakout above the $46.10 level, while a drop below $44.70 could trigger a sharper correction as long-term negative weekly signals remain unresolved.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk's strong Q1 results and robust demand for its GLP-1 franchise as clear positives. He believes the upbeat fundamental momentum and continued buyback program support the current price strength above key averages. However, the analyst notes overbought signals may cap immediate upside despite healthy macro sentiment. "The fundamental setup is strong, but in the near term I expect NVO to consolidate or retrace before a new move develops."

Earlier, analysts noted that Novo Nordisk's strong technical posture was tempered by overbought signals, suggesting a period of sideways consolidation amid elevated volatility. The current setup reinforces this view, with sustained buyer momentum but persistent overbought conditions highlighting a heightened risk of short-term pullback if key support levels falter.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.